1 of 1
SENATE DOCKET, NO. 1624 FILED ON: 1/16/2025
SENATE . . . . . . . . . . . . . . No. 1400
The Commonwealth of Massachusetts
_________________
PRESENTED BY:
Cindy F. Friedman
_________________
To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
An Act authorizing a pilot for the use of psychedelics in licensed treatment facilities.
_______________
PETITION OF:
NAME:DISTRICT/ADDRESS :Cindy F. FriedmanFourth Middlesex 1 of 2
SENATE DOCKET, NO. 1624 FILED ON: 1/16/2025
SENATE . . . . . . . . . . . . . . No. 1400
By Ms. Friedman, a petition (accompanied by bill, Senate, No. 1400) of Cindy F. Friedman for
legislation to authorize a pilot for the use of psychedelics in licensed treatment facilities. Mental
Health, Substance Use and Recovery.
The Commonwealth of Massachusetts
_______________
In the One Hundred and Ninety-Fourth General Court
(2025-2026)
_______________
An Act authorizing a pilot for the use of psychedelics in licensed treatment facilities.
Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
of the same, as follows:
1 Notwithstanding any general or special law to the contrary, the department of public
2health shall establish a pilot program to allow for the monitored mental health care of clinically
3appropriate patients using psychedelic materials as defined by the department of public health for
4on-site administration by a multi-disciplinary care team in a supervised licensed mental health
5clinic setting. The department shall issue pilot permits to no more than three licensed mental
6health clinic facilities to participate in the pilot program for the purposes of establishing the best
7and safest clinical practices for psychedelic mental health treatment programs in the
8commonwealth and for the purposes of collecting patient outcomes data regarding the benefits of
9psychedelic pharmacotherapy. Authorization shall be given to clinics licensed in mental health
10services as defined by the department of public health. Eligible pilot program organizations must
11exclusively focus operations and treatment on mental health and cannot be subsidiaries, affiliates
12or members of cannabis industry organizations, psychedelic molecule development companies or
13pharmaceutical companies. 2 of 2
14 The department shall promulgate the rules and regulations necessary for the operation of
15a supervised psychedelic pilot in a clinical setting, including but not limited to, establishing a
16process to apply for participation in the pilot. The regulations must include but not be limited to:
17the definitions and standards for clinic participation; the process of initial patient assessment and
18ongoing monitoring; the composition of the clinical staff and the role of a licensed physician to
19oversee the program; the process of ensuring coordination and medical management of
20psychiatric medications with prescribers outside of the participating outpatient clinical pilot; and,
21the process of storage, dispensing and administration of psychedelics within the participating
22pilot.
23 All pilot program participant organizations must track patient care outcomes data related
24to the identification, diagnosis and psychedelic treatment of depression, anxiety, post-traumatic
25stress disorder and substance use disorder. These data sets must be shared with the department to
26assist in the refinement of best clinical protocols and final regulatory frameworks for the safe use
27of psychedelic material in Massachusetts.